Whats your thoughts on this? Its from Locks posting.
Utilizing TCA Cellular’s proprietary therapy, a couple of thousand adult stem cells have been extracted from the patient’s own bone marrow, Mesenchymal Stem Cells have been separated, purified, multiplied to millions and will be infused into Cole’s spinal cord later this month.
In respect to what he calls CBAI, Largest, most signifigant, what the board likes, most profitable! Or what he ends the PR's with the most respected. I think we would all just like it to be the highest pps in the industry without R/S along the way.
Does anything in your research suggest we are pursuing any dominance over the business of multiplication of the cells? It would seem in the mulitiplication process there is a very good profit opprotunity, at a very strategic point in the entire transplantation process?
It would seem there would necesarilly be a cost in the multiplication process, I would think the point price would be very high, as I think we would agree the more stems the better for the patient.
Do you think there is more profit in this than storage itself? Do you think the lab is geared for that? If so I think that is one of the things he means when he talks about diversification of revenue streams.
Curious on your thoughts, and any research that indicates they are pursuing this. Thanks.